Kenning
Not started
Quick win kit · 7 days · yours forever

Nausea has a pattern.
Let’s find yours.

Nausea on these medications comes from several different mechanisms. Advice written for all of them lands on none of them.

  1. 1
    Name which nausea this isSeven questions, about two minutes
  2. 2
    Five days of only what matchesThree things a day, with a safety check each morning
  3. 3
    A plain verdict you keepIt rearms itself at your next dose increase
Seven question readFive day protocolDaily safety checkReusable at every dose increase
ONE

First, which nausea is this?

Six patterns. Only one of them is yours.

  • Dose response.Worst in the days after your injection.
  • Fat load.It arrives after richer food.
  • Volume and pace.Too much, too fast, and it turns.
  • Empty stomach.Long gaps make it worse, not better.
  • Reflux.It burns upward rather than sitting low.
  • Dehydration.Drinking less, feeling worse, drinking less.

They need opposite things, and generic advice speaks to none of them. Seven questions, about two minutes.

FOUR

When this is not ordinary nausea

Most of this is uncomfortable and temporary. A small number of things are not.

Read this once now, before you need it. The kit also checks for these every day, so remembering is not your job alone.

Same day

Contact your prescriber today if you have

  • Severe stomach pain that does not ease, especially pain that goes through to your back
  • Pain under your right ribs or into your right shoulder, particularly after a fatty meal
  • Vomiting that keeps going, or being unable to keep fluids down for a full day
  • Signs of dehydration: very little urine, dark urine, dizziness on standing, a dry mouth that will not resolve
  • No bowel movement for several days together with pain and a swollen stomach
  • Nausea that arrives suddenly and feels different in kind from what you have had before
  • Fever together with severe stomach pain or vomiting that will not stop
  • Vomiting blood, or passing black tar like stools
  • Severe or persistent vomiting when there is any chance you may be pregnant
If you cannot reach your prescriber and the pain is severe or you cannot keep fluids down, go to urgent care. Bring the summary page this kit makes for you.
Clinical content pending PharmD review · sources cited

If this happens again

You will not be starting over. When it comes back, most often at your next dose increase:

  1. Reopen this kit.
  2. Your previous plan is already saved.
  3. Compare what you are feeling now against your last episode.
  4. Change one thing at a time, so you learn something.
References
  1. How common, and when. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551. Nausea affected 43.9 percent of participants on semaglutide 2.4 mg against 16.1 percent on placebo, was reported more frequently during dose escalation, and cumulative incidence plateaued after around week 20.
  2. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336-347. doi:10.1111/dom.12824. Establishes that rates differ substantially by agent, dose and formulation, which is why this kit does not quote a single class wide figure.
  3. Managing it. Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. doi:10.3390/jcm12010145. Expert consensus covering how to reach the maintenance dose, how to proceed if gastrointestinal effects appear during escalation, and practical measures for nausea, vomiting, diarrhoea and constipation. This is the source for eating slowly, stopping at comfortable fullness, smaller portions, limiting high fat meals and staying upright. These measures are recommended by consensus; they have not been tested against one another in trials.
  4. Prescribing information. [VERIFY REVISION DATE BEFORE EACH RELEASE] Novo Nordisk Inc. Wegovy (semaglutide) injection, for subcutaneous use: US prescribing information. Plainsboro, NJ: Novo Nordisk Inc. NDA 215256. Revised 02/2026 (label supplement s033); a further labelling revision dated 06/2026 is reflected in the manufacturer posted PI. Novo Nordisk Inc. Wegovy (semaglutide) tablets: US prescribing information. NDA 218316. Revised 01/2026 (label supplement s002). Eli Lilly and Company. Zepbound (tirzepatide) injection, for subcutaneous use: US prescribing information. Indianapolis, IN: Eli Lilly and Company. NDA 217806. 2026 revision (label supplement s042). All list nausea, vomiting, diarrhoea and constipation among common adverse reactions, and all carry dose escalation guidance intended to reduce gastrointestinal adverse reactions. The Zepbound label reports discontinuation due to gastrointestinal adverse reactions in 3.3 percent at 10 mg and 4.3 percent at 15 mg against 0.5 percent on placebo. These labels are revised frequently. Always read the current version for the product you were actually prescribed.
  5. Where this sits in care. World Health Organization. WHO guideline on the use of GLP-1 therapies for the treatment of obesity in adults. Geneva: WHO; December 2025. Positions these therapies within comprehensive care including diet, physical activity and professional support.
  6. Spreckley M, Ruggiero CF, Brown A. Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery. Int J Obes. 2026;50:265-267. doi:10.1038/s41366-025-01952-w. Published online November 15, 2025. Sets out how little structured nutritional guidance accompanies these medications in practice.
  7. Ginger. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84(3):367-371. doi:10.1093/oxfordjournals.bja.a013442. And: Viljoen E, Visser J, Koen N, Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J. 2014;13:20. doi:10.1186/1475-2891-13-20. Extrapolated evidence. Ginger has randomised evidence for postoperative and pregnancy related nausea. It has not been tested for GLP-1 related nausea. It appears in this kit because it is low risk and some women find it helps, not because it has been shown to work for this.
  8. Why it matters for staying on treatment. Gastrointestinal symptoms are the most consistently reported self reported reason for stopping GLP-1 therapy. See references 1 to 3 and the WHO guideline above.
  9. Hormonal context. No source is cited for a claim that menopause stage or cycle phase determines whether nausea is medication related, because this kit no longer makes that claim. Sex hormones and menstrual phase may influence gastrointestinal motility and symptom perception in some women, but the evidence is heterogeneous. This kit records the pattern rather than assuming a cause.

How to read this list. References 1 to 3 and 5 are the evidence base for what this kit tells you. Reference 4 is the label for your own medication and outranks everything here. Reference 7 is explicitly extrapolated from other settings and is labelled as such wherever it appears. Where evidence is absent, as in reference 9, this kit says so rather than filling the gap.

Clinical content reviewed by a PharmD. Sources cited above.

Reviewed by Kenning's clinical and outcomes research team · educational only · not medical advice. Population specific thresholds pending PharmD review.